Article | May 14, 2021

Bayesian Methods & Vaccines Research: COVID-19

Source: Cytel

By Dr. Esha Senchaudhuri

vaccine

The urgent need to discover and assess the efficacy and safety of COVID-19 vaccine candidates will affect the future clinical development of all infectious disease vaccine candidates, including those for diseases like tuberculosis. An under-appreciated component of this change is the transformational role that Bayesian statistics has played in quality vaccines being quickly identified and assessed.

In a recent roundtable, a statistician who worked on the Pfizer vaccine joined my colleagues at Cytel who designed the BCG vaccine trial, as well as former CBER (FDA) expert and a member of the French Scientific Council to discuss these developments. Here I review the design features of these clinical trials, and why Bayesian methods reduced risk and generated scientific findings more quickly.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: